Everence Capital Management Inc. purchased a new stake in Axon Enterprise, Inc. (NASDAQ:AXON – Free Report) during the third quarter, HoldingsChannel reports. The firm purchased 1,360 shares of the biotechnology company’s stock, valued at approximately $543,000.
Other large investors have also added to or reduced their stakes in the company. Mather Group LLC. grew its holdings in Axon Enterprise by 3.7% in the 3rd quarter. Mather Group LLC. now owns 759 shares of the biotechnology company’s stock valued at $303,000 after buying an additional 27 shares in the last quarter. CWM LLC grew its holdings in Axon Enterprise by 1.3% in the 3rd quarter. CWM LLC now owns 2,856 shares of the biotechnology company’s stock valued at $1,141,000 after buying an additional 36 shares in the last quarter. SPC Financial Inc. grew its holdings in Axon Enterprise by 2.2% in the 3rd quarter. SPC Financial Inc. now owns 1,773 shares of the biotechnology company’s stock valued at $708,000 after buying an additional 38 shares in the last quarter. Dorsey Wright & Associates grew its holdings in Axon Enterprise by 0.3% in the 2nd quarter. Dorsey Wright & Associates now owns 14,053 shares of the biotechnology company’s stock valued at $4,135,000 after buying an additional 39 shares in the last quarter. Finally, Avantax Advisory Services Inc. grew its holdings in Axon Enterprise by 0.8% in the 1st quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock valued at $1,659,000 after buying an additional 40 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.
Insider Buying and Selling at Axon Enterprise
In other Axon Enterprise news, Director Michael Garnreiter sold 1,000 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $437.98, for a total value of $437,980.00. Following the completion of the transaction, the director now directly owns 26,259 shares in the company, valued at approximately $11,500,916.82. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Axon Enterprise news, Director Michael Garnreiter sold 1,000 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $437.98, for a total value of $437,980.00. Following the completion of the transaction, the director now directly owns 26,259 shares in the company, valued at approximately $11,500,916.82. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Julie A. Cullivan sold 900 shares of the stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $353.53, for a total value of $318,177.00. Following the completion of the transaction, the director now owns 3,653 shares of the company’s stock, valued at $1,291,445.09. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 371,172 shares of company stock worth $137,000,162. 6.10% of the stock is currently owned by insiders.
Axon Enterprise Stock Performance
Axon Enterprise (NASDAQ:AXON – Get Free Report) last posted its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $1.02 by $0.18. The firm had revenue of $504.00 million during the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The business’s quarterly revenue was up 34.5% on a year-over-year basis. During the same period last year, the company earned $0.80 earnings per share. On average, analysts anticipate that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.
Analysts Set New Price Targets
AXON has been the topic of several analyst reports. Bank of America initiated coverage on Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $380.00 target price on the stock. JMP Securities increased their target price on Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Robert W. Baird increased their target price on Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. Needham & Company LLC reissued a “buy” rating and set a $400.00 target price on shares of Axon Enterprise in a report on Wednesday, August 7th. Finally, Jefferies Financial Group initiated coverage on Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $385.00 target price on the stock. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $365.38.
Read Our Latest Analysis on Axon Enterprise
Axon Enterprise Company Profile
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Read More
- Five stocks we like better than Axon Enterprise
- What Are Dividend Challengers?
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- What Are Trending Stocks? Trending Stocks Explained
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- The Most Important Warren Buffett Stock for Investors: His Own
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON – Free Report).
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.